Cited 0 times in
Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, YG | - |
dc.contributor.author | Han, SJ | - |
dc.contributor.author | Kim, DJ | - |
dc.contributor.author | Lee, KW | - |
dc.contributor.author | Kim, HJ | - |
dc.date.accessioned | 2019-11-13T00:18:19Z | - |
dc.date.available | 2019-11-13T00:18:19Z | - |
dc.date.issued | 2018 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/16955 | - |
dc.description.abstract | BACKGROUND: Recently, two large randomized controlled trials which only included patients with underlying cardiovascular disease (CVD) or patients at high risk for CVD showed that two sodium glucose co-transporter 2 inhibitors (SGLT-2is) significantly reduced hospitalization for heart failure (hHF), with an early separation in the survival curves for hHF. There were concerns whether SGLT-2i use could protect hHF in patients without CVD and how soon SGLT-2i-treated patients show a lower risk of hHF. Thus, we aimed to evaluate whether the heart failure protective effect of SGLT-2i differs depending on the underlying CVD and the prescription period compared with dipeptidyl peptidase-4 inhibitors (DPP-4i).
METHODS: We performed a nationwide retrospective observational study to estimate the effect of SGLT-2i on HF. The 59,479 SGLT-2i new-users were matched with same number of DPP-4i new-users through propensity score matching using 53 confounding variables. Kaplan-Meier (K-M) curves and Cox proportional hazards regression analyses were used to estimate the risk of hospitalization for hHF. RESULTS: The incidence rates of hHF were 0.83 and 1.13 per 100 person-years in SGLT-2i-treated patients and DPP-4i-treated patients, respectively. The hazard ratios of hHF were 0.66 (95% confidence interval 0.58-0.75) in SGLT-2i-treated patients compared with the DPP-4i-treated patients. Among the patients with underlying CVD, SGLT-2i-treated patients were associated with a lower risk of hHF from 30 days to 3 years after initiating drugs compared with DPP-4i. However, SGLT-2i use only showed a lower risk of hHF with a significant difference 3 years after drug initiation among patients without underlying CVD. CONCLUSIONS: Our findings suggest that SGLT-2i reduced hHF compared with DPP-4i. A heart failure protective effect of SGLT-2i use vs. DPP-4i use was shown 30 days after initiating the SGLT-2i among patients with established CVD, but this effect appeared later in patients without established CVD. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Diabetes Mellitus, Type 2 | - |
dc.subject.MESH | Dipeptidyl-Peptidase IV Inhibitors | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Heart Failure | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Protective Factors | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Sodium-Glucose Transporter 2 Inhibitors | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study | - |
dc.type | Article | - |
dc.identifier.pmid | 29935543 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015464/ | - |
dc.subject.keyword | Heart failure | - |
dc.subject.keyword | Type 2 diabetes mellitus | - |
dc.subject.keyword | Sodium glucose co-transporter 2 inhibitors dipeptidyl peptidase-4 inhibitor | - |
dc.contributor.affiliatedAuthor | 한, 승진 | - |
dc.contributor.affiliatedAuthor | 김, 대중 | - |
dc.contributor.affiliatedAuthor | 이, 관우 | - |
dc.contributor.affiliatedAuthor | 김, 혜진 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1186/s12933-018-0737-5 | - |
dc.citation.title | Cardiovascular diabetology | - |
dc.citation.volume | 17 | - |
dc.citation.number | 1 | - |
dc.citation.date | 2018 | - |
dc.citation.startPage | 91 | - |
dc.citation.endPage | 91 | - |
dc.identifier.bibliographicCitation | Cardiovascular diabetology, 17(1). : 91-91, 2018 | - |
dc.identifier.eissn | 1475-2840 | - |
dc.relation.journalid | J014752840 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.